Stopping risperidone abruptly can trigger a range of withdrawal symptoms, from nausea and insomnia to involuntary movements and, in some cases, a return or worsening of the very psychotic symptoms the drug was prescribed to treat. These effects stem from the brain’s adaptation to the drug’s presence, particularly its blockade of dopamine and serotonin receptors. The severity varies widely between individuals, but the medical consensus is clear: risperidone should almost never be stopped cold turkey.
The Withdrawal Symptoms People Actually Experience
A large survey of 585 people who tried to withdraw from antipsychotic drugs found that roughly three out of four reported classical withdrawal effects, the same kinds seen with other drugs that act on the central nervous system. The most common complaints were nausea, tremors, anxiety, agitation, and headaches. About half of those who experienced withdrawal rated it as severe. Insomnia, nervousness, and extreme emotional states topped the list in open-ended responses. A smaller group, about one in four, reported positive changes like feeling more energetic or thinking more clearly, but these were outnumbered by the people struggling with the transition.1Elsevier / ScienceDirect. The experiences of 585 people when they tried to withdraw from antipsychotic drugs
Clinical guidelines on switching antipsychotic medications have long recognized that discontinuation can produce insomnia, nausea, vomiting, anxiety, and agitation as stand-alone withdrawal signs, separate from any relapse of the underlying psychiatric condition.2PubMed. Changing antipsychotic medication: guidelines on the transition to treatment with risperidone The challenge for both patients and clinicians is distinguishing between a withdrawal reaction that will pass in time and a genuine return of the illness. In practice, the two can overlap, making the situation even harder to manage.
Involuntary Movements and Akathisia
Some of the most alarming withdrawal effects involve movement. Tardive dyskinesia, a condition marked by repetitive involuntary movements like lip smacking, tongue protrusion, and limb twitching, can emerge when risperidone is stopped abruptly. A case report documented a six-year-old boy with autism and ADHD who developed unsteady gait, twisting fingers, shoulder shrugging, and a protruding tongue with excess saliva just two days after his risperidone was suddenly discontinued.3PubMed Central. Risperidone Abruption-Induced Tardive Dyskinesia in a Six-Year-Old Male Patient With Known Autism and Attention Deficit Hyperactivity Disorder: A Case Report In an elderly patient with mixed dementia, abrupt withdrawal triggered dyskinesia at multiple sites, including the respiratory muscles, limbs, and face.4Clinical Neuropharmacology. Risperidone Withdrawal-Related Respiratory Dyskinesia
Akathisia, an intensely uncomfortable feeling of inner restlessness that makes it almost impossible to sit still, is another documented withdrawal effect. A case report described a 17-year-old girl who developed akathisia after stopping risperidone.5PubMed Central. Akathisia Induced by Abrupt Withdrawal of Risperidone: A Case Report Akathisia is often mistaken for anxiety or agitation, which can lead to misdiagnosis and inappropriate treatment if the clinician does not connect the symptom to the recent drug stoppage.
Why the Brain Reacts This Way
Risperidone works primarily by blocking dopamine receptors in the brain. When the drug is taken regularly, the brain compensates by becoming more sensitive to dopamine, essentially turning up its own volume to counteract the blockade. When risperidone is removed suddenly, that heightened sensitivity is left unopposed. Dopamine floods receptors that are now primed to overreact, which can produce movement disorders, psychotic symptoms, or both. Researchers describe this as dopamine supersensitivity. In animal studies, rats treated with risperidone and then withdrawn showed increased responses to drugs that stimulate dopamine activity, confirming that the brain’s dopamine system had been upregulated during treatment.6PubMed Central. Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5-HT(2A) receptors in rats
Dopamine is not the only neurotransmitter involved. Risperidone also blocks serotonin and cholinergic receptors. Abrupt withdrawal can unmask rebound effects at these sites too, which is why the symptom picture can be so varied. Nausea, sweating, and digestive problems often reflect cholinergic rebound, while anxiety and mood instability may partly stem from serotonin receptor changes.7PubMed Central. A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse The multi-receptor involvement helps explain why withdrawal from risperidone can feel so physically overwhelming, rather than just a mental health relapse.
How Long Risperidone Stays in Your System
Risperidone itself is processed fairly quickly. In most people, the drug has a half-life of about 3 hours. But it gets converted in the body to an active metabolite called 9-hydroxyrisperidone, which has very similar effects. When you combine the parent drug and its metabolite, the “active fraction” has a half-life of roughly 20 hours regardless of how quickly you personally metabolize the drug.8PubMed. The pharmacokinetics of risperidone in humans: a summary That means the drug’s effects wear off within a few days of the last dose, which is fast enough that withdrawal symptoms can begin within 24 to 48 hours of stopping. The speed of clearance is part of what makes abrupt cessation risky: the brain’s adapted state does not reset nearly as quickly as the drug leaves the bloodstream.
This mismatch between drug clearance and neural adaptation is the core of the problem. Your body eliminates risperidone in days, but your brain’s receptor changes can take weeks or months to normalize. That gap is where withdrawal symptoms live.
The Risk of Psychosis Returning
For people taking risperidone for schizophrenia or other psychotic disorders, the biggest concern with stopping abruptly is relapse. Clinical guidelines note that relapse of psychosis occurs in most patients with psychotic disorders after antipsychotic discontinuation, and sometimes this happens many months later, not just in the immediate withdrawal window.9PubMed Central. Stopping and switching antipsychotic drugs The distinction between a withdrawal-related psychotic episode and a true relapse matters clinically: withdrawal psychosis tends to be shorter-lived and may resolve as the brain readjusts, while a relapse signals that the underlying condition still needs treatment. In practice, though, clinicians often cannot tell the difference in real time, which is one reason abrupt discontinuation is so strongly discouraged.
The survey data mentioned earlier found that about 18% of people who tried to withdraw from antipsychotics reported experiencing psychosis during the process.1Elsevier / ScienceDirect. The experiences of 585 people when they tried to withdraw from antipsychotic drugs Whether that figure reflects genuine relapse or withdrawal-triggered psychosis in every case is impossible to say, but it underscores why medical supervision matters.
Children and Adolescents Face Distinct Risks
Risperidone is widely prescribed to children, particularly those with autism spectrum disorder and ADHD, to manage irritability and aggressive behavior. Withdrawal risks in this population deserve special attention. A study on children with autism found that stopping risperidone after six months of treatment significantly increased the risk of relapse of behavioral symptoms.10Evidence Based Mental Health. Discontinuing risperidone results in relapse in children with autism spectrum disorders
Withdrawal dyskinesia in children has been documented as well. A case study described a 13-year-old boy with ADHD and conduct disorder who developed mouth movements, neck twisting, and intermittent upward eye rolling two weeks after stopping risperidone.11PubMed Central. Risperidone Withdrawal Symptoms Perhaps more concerning is a case of a 13-year-old girl with autism and intellectual disability who developed catatonia, a state involving altered consciousness, rigid posturing, and bizarre motor behaviors, following discontinuation of risperidone. Her symptoms included negativism, grimacing, and waxy flexibility, and they emerged shortly after the drug was stopped.12PubMed Central. Case of paediatric catatonia precipitated by antipsychotic withdrawal in a child with autism spectrum disorder Catatonia is a medical emergency, and its appearance in this context suggests that abrupt withdrawal in children with neurodevelopmental conditions carries risks that go beyond what most parents would expect.
Who Is Most Vulnerable
The research on risk factors for antipsychotic withdrawal is thinner than you might expect, but a few patterns have emerged. A systematic review noted that withdrawal symptoms were reported at significantly higher rates in women and in people over 50. One study of a geriatric population found that 72% of individuals experienced withdrawal symptoms after discontinuation.13Frontiers in Psychiatry. Antipsychotic Withdrawal Symptoms: A Systematic Review and Meta-Analysis Whether higher doses lead to worse withdrawal remains surprisingly unclear. A couple of older studies found no significant dose effect, but those studies only looked at moderate dose ranges, so the question of whether people on very low doses have an easier time remains open.
Duration of treatment almost certainly matters, though. The longer you take risperidone, the more time the brain has to adapt to its presence, and the more dramatic the adjustment period when it is removed. This is consistent with the general principle seen across most central nervous system medications: longer exposure tends to mean a harder withdrawal.
Why People Stop Abruptly in the First Place
Knowing the risks, it might seem puzzling that anyone would quit risperidone cold turkey. But the reasons are practical and often understandable. A study examining why people discontinue antipsychotics found that the most common single reason was that positive symptoms were not sufficiently improved or were made worse by the medication, followed by side effects.14PubMed. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives
Weight gain is a particularly powerful driver. A meta-analysis found that antipsychotics with moderate weight gain liability, a category that includes risperidone, more than doubled the odds of nonadherence or discontinuation compared to drugs with lower weight gain risk.15PubMed Central. The impact of weight gain on antipsychotic nonadherence or discontinuation: A systematic review and meta-analysis Other common side effects of risperidone, like sedation, sexual dysfunction, and hormonal changes, also push people toward stopping. When the medication feels worse than the condition it treats, some people simply stop filling prescriptions without telling their doctor. The result is an unplanned, unsupervised withdrawal.
Qualitative research paints a more nuanced picture. Many people considering dose reduction are caught between wanting to escape side effects and fearing the return of symptoms. Caregivers, meanwhile, often oppose any reduction, driven by anxiety about relapse and the emotional and safety consequences it could bring for the whole family.16Schizophrenia. Dose reduction and discontinuation of antipsychotics in psychotic disorders: a systematic review of qualitative studies and meta-synthesis This tension between a person’s lived experience of side effects and a caregiver’s fear of relapse is one of the most difficult dynamics in antipsychotic treatment.
How Tapering Should Actually Work
The evidence strongly favors a gradual, slow taper over abrupt discontinuation. But “gradual” here means something specific, and it is slower than most people expect. Researchers have proposed that antipsychotic dose reductions should follow a hyperbolic pattern: each reduction should be a fraction (roughly a quarter to a half) of the most recent dose, with intervals of three to six months between reductions. This means the absolute size of each dose cut gets smaller and smaller as you approach zero.17Schizophrenia Bulletin. A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
The logic is neurobiological. Because of how drug concentration relates to receptor occupancy, the final milligrams of a dose occupy a disproportionate share of receptors. Cutting from 4 mg to 2 mg might feel manageable, but cutting from 1 mg to zero removes a larger proportion of the remaining receptor blockade than it seems on paper. Making smaller reductions at lower doses, and spacing them out, gives the brain time to recalibrate at each step.18PubMed Central. Gradually tapering off antipsychotics: lessons for practice from case studies and neurobiological principles The total taper period can stretch to a year or longer. For someone desperate to be off the drug, that feels like an eternity, but the alternative, a relapse or severe withdrawal that lands them back on a higher dose, is usually worse.
General guidance on antipsychotic discontinuation recommends reducing and stopping slowly, ideally over weeks to months, and remaining alert to the possibility that relapse can occur many months after the final dose.9PubMed Central. Stopping and switching antipsychotic drugs Monitoring for withdrawal signs is important at every step, and any taper plan should be adjusted based on how the individual responds.
The Role of Informed Consent and Shared Decisions
One of the most persistent problems in antipsychotic treatment is the gap between what patients want and what clinicians offer. Many people want to explore dose reduction or discontinuation, but feel their concerns are dismissed. An international survey found that evidence-based, respectful, collaborative responses to patients’ concerns about side effects and their desire to withdraw would likely reduce relapse rates and improve long-term outcomes, while also ending what the researchers described as pervasive breaching of the principle of informed consent.19PubMed. What is helpful and unhelpful when people try to withdraw from antipsychotics: An international survey
Simple strategies can make a real difference. Shared decision-making, regular assessment of adherence, managing side effects proactively, and building a genuine therapeutic relationship between clinician and patient all support better outcomes.20PubMed Central. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies When people feel heard and involved in decisions about their medication, they are less likely to take matters into their own hands by stopping without guidance. The irony is that abrupt cessation, with all its dangers, is often a consequence of patients feeling they have no other option.
When Switching Rather Than Stopping
Sometimes the goal is not to come off antipsychotics entirely but to switch to a different one with a better side-effect profile. Even in this scenario, abrupt cessation of risperidone is risky. Clinical guidelines emphasize that the transition should overlap, gradually introducing the new medication while slowly tapering the old one. Stopping risperidone cold and starting a new drug the next day invites a period of withdrawal symptoms from risperidone layered on top of the adjustment effects of the new medication. The combination can include reemergence of psychosis, dyskinesia, and cholinergic rebound symptoms.2PubMed. Changing antipsychotic medication: guidelines on the transition to treatment with risperidone
Interestingly, some antipsychotics may be better than others at smoothing out the withdrawal from risperidone. Animal research has shown that certain drugs with partial agonist activity at dopamine receptors can suppress the rebound phenomena that arise after risperidone withdrawal, essentially calming down the hypersensitized dopamine system during the transition.6PubMed Central. Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5-HT(2A) receptors in rats This is still an area of active research rather than established clinical practice, but it reflects a growing awareness that how you leave one antipsychotic matters as much as which one you move to next.